Name | fmrf amide |
---|---|
Synonyms |
h-phe-met-arg-phe-nh2 acoh
fmrf-nh2 phe-met-arg-phe-nh2 molluscan cardioexcitatory peptide fmrfamide acetate salt phe-met-arg-phe-nh2 1/2acoh 2h2o h-phe-met-arg-phe-nh2 phe-met-arg-phe amide fmrf-amide 1 1/2acoh 2h2o |
Description | Phe-Met-Arg-Phe, amide acetate dose dependently (ED50=23 nM) activates a K+ current in the peptidergic caudodorsal neurons[1]. |
---|---|
Related Catalog | |
Target |
ED50: 23 nM (K+ current)[1] |
In Vitro | In the molluscan central nervous system, Phe-Met-Arg-Phe, amide (FMRFa) acetate acts on K+ channels in sensory, motor-, and neuroendocrine neurones. Phe-Met-Arg-Phe, amide acetate activates a novel K+ current that is characterized by a combined voltage- and receptor-dependent gating mechanism, with both factors being necessary for opening of the channels[1]. Phe-Met-Arg-Phe, amide (1 μM) acetate significantly inhibits glucose stimulated (300 mg/dL) insulin release (p<0.005) and somatostatin release (p<0.01) from the isolated perfused pancreas[2]. Phe-Met-Arg-Phe, amide (FMRF-NH2) (1 and 10 μM) acetate is without effect on glucagon secretion, either in low glucose (50 mg/dL), high glucose (300 mg/dL), or during arginine stimulation (5 mM)[2]. |
In Vivo | Phe-Met-Arg-Phe, amide (FMRFamide) acetate stimulates growth hormone secretion in conscious OVX rats. The presence of Phe-Met-Arg-Phe, amide-like immunoreactivity in neuronal elements in the hypothalamus suggested a role for this in the hypothalamic control of the anterior pituitary function. The injection of 200 ng (313.8 pM) of FMRFamide (in 2 uL) produces a significantly increased plasma GH 15 min after injection. The GH-increasing effect of 400-800 ng (627-1255 pM) of FMRFamide is already developed after 5 min and lasted up to 30 min[3]. |
References |
Molecular Formula | C31H46N8O6S |
---|---|
Molecular Weight | 658.81 |
Exact Mass | 598.30500 |
PSA | 243.61000 |
LogP | 3.51940 |